The recent endorsement by the National Institute for Health and Care Excellence (NICE) to utilize AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy as a treatment for adults with resectable non-small cell lung cancer (NSCLC) marks a significant milestone in cancer care. This
In a significant breakthrough, Poolbeg Pharma announced positive pre-clinical study results for their drug POLB 001, presented at the 66th American Society of Hematology (ASH) Annual Meeting. The study focused on the drug's potential to prevent Cytokine Release Syndrome (CRS), a frequently observed
A recent study spearheaded by University of South Florida (USF) Health researchers, in collaboration with TGH Cancer Institute, has unveiled a potential link between ultra-processed foods and an increased risk of colorectal cancer. Researchers highlighted how these foods may contribute to chronic
In early 2023, the FDA's announcement of a shortage of two critical generic platinum chemotherapy drugs, cisplatin and carboplatin, alarmed the medical community. These drugs have been essential in the treatment of various advanced cancers for over 30 years, particularly lung, head and neck,
Advancements in cancer therapy have brought significant hope, especially with immune checkpoint blockades (ICBs), providing a groundbreaking treatment strategy for advanced cancers. Despite this, the effectiveness of ICBs has often been thwarted by therapeutic resistance, which renders
The Keck School of Medicine of USC has embarked on a groundbreaking research initiative aimed at addressing age-related cognitive decline in women. This significant effort is led by Dr. Young-Kwon Hong and has been bolstered by securing a $3.4 million federal grant from the Advanced Research
